Ulipristal acetate on quality of life and sexual function of women with uterine fibromatosis

Abstract

To evaluate quality of life and sexual function of childbearing-age women, affected by uterine fibromatosis undergoing medical treatment with ulipristal acetate. The data obtained by filling the questionnaires European Quality of Life Five-Dimension Scale and modified Female Sexual Function Index, were analyzed to assess UPA usefulness in improving QoL and sexual activity. A total of 139 patients affected by uterine fibromatosis undergoing conservative ulipristal acetate treatment were enrolled in this prospective observational cohort study. Seventy-one women (average age 46.5 years) answered the questionnaires: QoL and sexuality were evaluated before and after ulipristal acetate treatment. 59 patients (83.1%) had an improvement of QoL and general health state, with a reduction of VAS score after ulipristal acetate treatment. EQ-5D-5L showed a statistically significant improvement of usual act impairment, mobility, discomfort, anxiety/depression (p < .0005). There was no difference in personal care management after therapy. Modified FSFI showed a statistically significant improvement (p < .0001) of sexual satisfaction and sexual life. A not statistically significant improvement in dyspareunia was also highlighted. This study provides a clear picture about QoL impact on women and confirms the effectiveness of the ulipristal acetate in improving different aspects of daily and sexual life of patients undergoing medical treatment.

摘要

目的是评估受子宫纤维瘤病影响并接受醋酸乌利司他治疗的育龄妇女的生活质量和性功能。通过分析患者填写的欧洲五项生活质量量表和改良的女性性功能指数问卷的数据, 评估UPA在改善QoL和性生活方面的有效性。在这项前瞻性观察性队列研究中, 总共纳入了139例接受保守性醋酸乌利司他治疗的子宫纤维瘤病患者。71名妇女（平均年龄46.5岁）填写了问卷：醋酸乌利司他治疗前后的生活质量和性生活均得到了评估。醋酸乌利司他治疗后59例患者（占83.1％）的QoL和总体健康状况得到改善, VAS评分降低。 EQ-5D-5L显示, 日常活动受损, 行动能力, 不适感, 焦虑/抑郁在统计学上显著改善（p <.0005）。治疗前后的自我照顾能力没有差异。改良的FSFI显示治疗后性满意度和性生活在统计学上有显著改善（p <.0001）。也应强调性交困难的改善无统计学意义。这项研究清晰地描述了子宫纤维瘤对妇女QoL的影响, 并证实了醋酸乌利司他在改善接受治疗的患者的日常生活和性生活的不同方面的有效性。

The Chinese abstracts are translated by Prof. Dr. Xiangyan Ruan and her team: Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China.

Keywords:

• Uterine fibromatosis
• ulipristal acetate
• quality of life
• sexual life
• selective progesterone receptor modulator
• medical treatment

Disclosure statement

No potential conflict of interest was reported by the authors.